Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Lung adenocarcinoma — EGFR disease

TL;DR — EGFR-mutant adenocarcinoma is the foundational biomarker-defined lung cancer. IPASS showed that gefitinib improved PFS only in mutation-positive tumors (HR 0.48) and harmed the mutation-negative subgroup relative to chemotherapy (HR 2.85), establishing genotype—not demographic phenotype—as the treatment selector (Mok 2009, PMID 19692680). Osimertinib became the metastatic first-line backbone through FLAURA, improving PFS and overall survival with strong CNS activity (Soria 2018, PMID 29151359; Ramalingam 2020, PMID 31751012). First-line intensification with platinum-pemetrexed or amivantamab-lazertinib prolongs PFS and, at final analysis, overall survival (FLAURA2 OS HR 0.77; MARIPOSA OS HR 0.75), but roughly doubles or adds substantially to grade ≥3 toxicity, so selection rather than efficacy is now the open question (Planchard 2023, PMID 37937763; Jänne 2026, PMID 41104938; Cho 2024, PMID 38924756; Yang 2025, PMID 40923797). In resected stage IB–IIIA disease, three years of adjuvant osimertinib improved DFS and OS, but duration, retreatment, and cure fraction remain active questions (Wu 2020, PMID 32955177; Tsuboi 2023, PMID 37272535).

The biomarker-defined disease

EGFR class Examples Sensitivity frame
Classical sensitizing Exon 19 deletion, L858R Osimertinib-based first line
Uncommon sensitizing G719X, L861Q, S768I Variable; afatinib/osimertinib evidence mostly non-randomized
Exon 20 insertion Diverse in-frame insertions Resistant to conventional-dose first/third-generation TKIs; amivantamab-based strategy
Primary resistant Many exon 20 insertions, rare kinase-domain variants Variant-specific interpretation needed
Acquired resistance T790M after early TKIs; C797S after osimertinib Treatment-history and allelic context matter

EGFR prevalence is population-dependent. PIONEER found mutations in 51.4% of 1,450 evaluable advanced Asian adenocarcinomas, with country, sex, ethnicity, and smoking effects (Shi 2014, PMID 24419411). Never-smoking phenotype enriches probability but cannot replace testing.

IPASS and the predictive-biomarker lesson

IPASS randomized clinically selected East Asian never/light smokers with pulmonary adenocarcinoma to gefitinib or carboplatin-paclitaxel. In EGFR-mutant tumors, gefitinib improved PFS (HR 0.48); in EGFR-wild-type tumors, chemotherapy was superior (gefitinib HR 2.85) (Mok 2009, PMID 19692680).

IPASS lesson Consequence
Clinical enrichment produced a mixed molecular population Never-smoker/Asian/female phenotype is insufficient
Treatment effect reversed by mutation status EGFR is predictive, not merely prognostic
Crossover diluted OS separation PFS and treatment sequence require joint interpretation
Tissue availability constrained subgroup analysis Reflex testing became a system requirement

First-line metastatic therapy

Strategy Trial Efficacy signal Principal trade-off
Osimertinib FLAURA PFS 18.9 vs 10.2 mo, HR 0.46; OS 38.6 vs 31.8 mo, HR 0.80 (Soria 2018, PMID 29151359; Ramalingam 2020, PMID 31751012) Acquired resistance; chronic cardiac/QTc/ILD monitoring
Osimertinib + platinum-pemetrexed FLAURA2 Investigator-assessed PFS 25.5 vs 16.7 mo, HR 0.62 (Planchard 2023, PMID 37937763); final OS 47.5 vs 37.6 mo, HR 0.77 (95% CI 0.61–0.96) (Jänne 2026, PMID 41104938) Grade ≥3 adverse events 70% vs 34%; chemotherapy burden front-loaded, with grade ≥3 onset falling from 43% in induction to 14% once on osimertinib alone (Planchard 2026, PMID 42728193)
Amivantamab + lazertinib MARIPOSA PFS 23.7 vs 16.6 mo vs osimertinib, HR 0.70 (Cho 2024, PMID 38924756); final OS HR 0.75 (95% CI 0.61–0.92), 3-year OS 60% vs 51% (Yang 2025, PMID 40923797) Grade ≥3 adverse events 80% vs 52%; infusion reactions, rash, paronychia, edema, VTE; IV burden
Osimertinib + platinum-pemetrexed in EGFR/TP53 co-mutant disease Chinese phase 3 (NCT04695925) PFS 34.0 vs 15.6 mo, HR 0.44; OS immature at 30.6% maturity (Zhou 2026, PMID 42574006) Co-mutation-restricted randomized trial; single-country population

Osimertinib’s CNS penetration is clinically load-bearing because EGFR disease has high lifetime brain-metastasis risk. FLAURA reduced CNS progression versus first-generation comparators, but surveillance intervals and local treatment still depend on lesion burden and symptoms (Soria 2018, PMID 29151359).

Intensification should not be described as universally superior, but the earlier caveat that overall survival was unproven no longer holds: both FLAURA2 and MARIPOSA met their key secondary OS endpoints against osimertinib monotherapy (Jänne 2026, PMID 41104938; Yang 2025, PMID 40923797). These are two different comparators and have not been compared with each other. What remains open is who needs it. The TP53-restricted trial above tests intensification within a co-mutation-defined group, but it did not randomize TP53-wild-type patients, so it shows benefit in the subgroup without showing that TP53 status predicts benefit (Zhou 2026, PMID 42574006). A 25-institution Japanese cohort derived a 0–6-point score for long-term benefit on osimertinib alone (5–6 points: median OS 68.3 months); its authors state it is prognostic and does not establish whether monotherapy should be preferred (Ishida 2026, PMID 42767607). In MARIPOSA, amivantamab-lazertinib reduced acquired MET amplification (3.4% vs 13.1%) and secondary EGFR mutations (1.4% vs 7.6%) in end-of-treatment plasma (Hayashi 2026, PMID 42061572).

Adjuvant EGFR therapy

ADAURA randomized completely resected stage IB–IIIA classical EGFR-mutant NSCLC to osimertinib or placebo for three years after optional standard chemotherapy. The primary stage II–IIIA DFS HR was 0.17 in the initial report; the overall stage IB–IIIA DFS HR was 0.20 (Wu 2020, PMID 32955177). Mature analysis showed an overall-survival benefit, HR 0.49, with 5-year OS 88% versus 78% in stage IB–IIIA (Tsuboi 2023, PMID 37272535). A post hoc 8-year landmark update (431 of 558 surviving patients with extended follow-up; 127 censored at the earlier cutoff) reported OS HR 0.52 and 8-year OS 79% versus 64% in stage IB–IIIA, with the exon-19-deletion HR (0.45) lower than the L858R HR (0.72, CI crossing 1) (Wu 2026, PMID 42732874). In ICWIP, three years of adjuvant icotinib after four cycles of chemotherapy in 135 patients improved DFS (HR 0.54) without a detectable OS difference (HR 0.84, 95% CI 0.39–1.81) (Liu 2026, PMID 42660909).

ADAURA question What is known What remains open
Does it delay recurrence? Large DFS effect including CNS recurrence reduction (Wu 2020, PMID 32955177) No
Does it improve OS? OS HR 0.49 in mature analysis (Tsuboi 2023, PMID 37272535) Magnitude under contemporary salvage
Is chemotherapy replaced? No; chemotherapy remained standard when indicated Optimal integration by stage and risk
Why three years? Trial-defined duration Whether shorter/longer or ctDNA-guided duration is better
Can relapse be retreated? Some tumors remain sensitive Prospective retreatment probability and sequencing

ALINA and perioperative immunotherapy make rapid preoperative genotyping equally important for non-EGFR drivers and for avoiding immune therapy in oncogene-driven tumors where benefit is uncertain.

Acquired resistance to earlier-generation TKIs

T790M increases ATP affinity and accounts for a large fraction of resistance after gefitinib/erlotinib/afatinib. AURA3 randomized T790M-positive progression to osimertinib versus platinum-pemetrexed: PFS 10.1 versus 4.4 months, HR 0.30, establishing re-biopsy-driven therapy (Mok 2017, PMID 27959700).

Mechanism after early TKI Detection Treatment implication
EGFR T790M Tissue or plasma; plasma-negative requires tissue Osimertinib
MET amplification Copy-number analysis, context-dependent threshold MET-directed combination trials/strategies
HER2 amplification / bypass Broad profiling Trial or pathway-directed strategy
Small-cell transformation Tissue morphology + RB1/TP53 context Small-cell chemotherapy framework
Histologic transformation Tissue Treatment follows transformed phenotype

Resistance after first-line osimertinib

Resistance is polyclonal and includes EGFR C797S, MET amplification, acquired fusions, RAS–MAPK reactivation, HER2 alterations, and small-cell/squamous transformation. C797S disrupts covalent osimertinib binding; whether it occurs in cis or trans with T790M determines theoretical sensitivity to combinations, but this is most relevant after sequential earlier-generation therapy (Roper 2020, PMID 32483558).

Pattern Why plasma helps Why tissue still matters
Multiple genomic clones Captures DNA shed across lesions Low shedding can miss mechanisms
MET amplification May be detected across sites Copy-number calling is purity-sensitive
C797S and compound mutations Reveals allelic mixtures Phasing may be incomplete
Transformation Often no unique plasma signature Requires morphology and immunophenotype

EGFR/TP53 co-mutant tumors with chromosomal instability and genome doubling are more likely to show mixed lesion-level TKI response, supporting combined radiographic and molecular assessment rather than a single RECIST summary (Hobor 2024, PMID 38871738).

Post-osimertinib strategy

Platinum-pemetrexed remains a backbone when no matched resistance mechanism exists. Amivantamab-based combinations target EGFR and MET and are moving earlier; the clinically important comparison includes efficacy, infusion burden, thromboembolism, skin/nail toxicity, and access (MARIPOSA programme, PMID 38942080).

Post-third-generation-TKI regimen Design Result Boundary
Ivonescimab (PD-1×VEGF bispecific) + carboplatin-pemetrexed vs placebo + chemotherapy HARMONi, double-blind phase 3, n=438 (NCT06396065) PFS 6.8 vs 4.4 mo, HR 0.52; OS 16.8 vs 14.0 mo, HR 0.79 (95% CI 0.62–1.01) (Le 2026, PMID 42636833) OS co-primary not met at this analysis; serious treatment-related AEs 28% vs 15%; a correction notice has been published (PMID 42805208)
Ivonescimab + pemetrexed-carboplatin vs placebo + chemotherapy HARMONi-A, double-blind phase 3, China, n=322 (NCT05184712) OS 16.8 vs 14.1 mo, HR 0.74 (0.58–0.95); 30-month OS 29.1% vs 18.4%; grade ≥3 TEAEs 67.1% vs 54.7% (Fang 2026, PMID 42307937) China-only; OS is the key secondary endpoint after PFS. Distinct from global HARMONi, whose OS co-primary was not met
Izalontamab brengitecan (EGFR×HER3 ADC) vs platinum-pemetrexed PANKU-Lung01, open-label phase 3, China, n=422 treated (NCT06382116) PFS 11.1 vs 5.7 mo, HR 0.40; grade ≥3 TRAEs 79% vs 62%; treatment-related ILD 1% vs 0% (Hong 2026, PMID 42933461) China-only; final PFS, interim OS (OS numbers not in the abstract); haematological toxicity
Ruzaltatug rezetecan (HER3 ADC) vs platinum-pemetrexed HERON-Lung01, open-label phase 3, China, n=498 (NCT06671379) Interim PFS 8.3 vs 5.4 mo, HR 0.47; grade ≥3 TRAEs 41% vs 39% (Xu 2026, PMID 42933457) China-only; median follow-up 7.7 months; one possibly treatment-related death
Dalmelitinib + aumolertinib vs platinum chemotherapy Chinese phase 3, EGFR-mutant MET-amplified after EGFR-TKI, n=314 (NCT06110663) PFS 6.2 vs 4.4 mo, HR 0.60; ORR 59.6% vs 38.6%; OS immature (Li 2026, PMID 42928710) FISH MET copy ≥5 or MET/CEP7 ≥2; registry record UNKNOWN since 2023-11-01
Amivantamab + lazertinib + bevacizumab, chemotherapy-free AMAZE-lung, single-arm phase 2, n=61 (NCT05601973) 12-week ORR 33% in the first 60 patients (Soo 2026, PMID 42833236) No comparator; grade 3–4 treatment-related AEs 43%; treatment-related VTE 17%

Correction check, 2026-10-23. PubMed links the HARMONi report to its correction (PMIDs: 42636833, 42805208), and Crossref identifies an erratum rather than a retraction. The correction full text returned HTTP 403. Whether it changes the figures above remains [unverified]; they have not been reverified against the corrected full text.

For asymptomatic, low-burden brain metastases, the STARLET pooled analysis of two randomized phase 2 trials (OUTRUN, NCT03497767; LUOSICNS, NCT03769103; n=79) found no significant 12-month intracranial-PFS gain from adding upfront stereotactic radiosurgery to osimertinib (median 21.9 vs 17.2 months; p=0.31), with 5% grade 3/4 radionecrosis in the SRS arm; median OS was 46.1 versus 29.1 months but was a secondary endpoint in a small trial (Lee 2026, PMID 41534788).

Local ablative therapy can control a small number of progressing sites while continuing osimertinib when most disease remains suppressed. A 2026 meta-analysis of 16 randomized oligometastatic NSCLC trials (1,343 patients) reported OS HR 0.68 overall and OS HR 0.52 in EGFR-mutant subgroups receiving EGFR TKIs, with more grade ≥3 adverse events and pneumonitis (Xu 2026, PMID 42955614). The analysis does not define molecular oligoprogression or isolate a TKI-continuation-plus-ablation rule from a switch rule; numbers are from the abstract.

EGFR exon 20 insertion disease

Exon 20 insertions are structurally heterogeneous and usually insensitive to conventional-dose EGFR TKIs. PAPILLON randomized first-line amivantamab plus carboplatin-pemetrexed versus chemotherapy: median PFS 11.4 versus 6.7 months, HR 0.40 (Zhou 2023, PMID 37870976).

Exon 20 issue Clinical consequence
Variant diversity Assay must cover insertions beyond hotspot probes
Antibody therapy Infusion reaction, dermatologic toxicity, edema, VTE monitoring
CNS disease Antibody CNS penetration is limited; brain-specific strategy remains important
Older targeted agents Regulatory status and availability have changed; use current guideline version

Safety and sequencing

Toxicity Signal Control
Interstitial lung disease/pneumonitis Rare but potentially fatal across EGFR TKIs Hold for new respiratory symptoms; investigate urgently
QTc prolongation Osimertinib ECG/electrolytes in at-risk patients
Cardiomyopathy Osimertinib LVEF assessment when indicated
Rash/diarrhea/paronychia EGFR pathway class effect Proactive dermatologic/GI management
Infusion reaction Amivantamab, especially first infusion Split first dose/premedication/monitoring
VTE Amivantamab-lazertinib signal Risk awareness and protocol-based prophylaxis where recommended

Checkpoint inhibitor before EGFR TKI can complicate sequencing through pneumonitis/hepatitis risk. In a clinically stable patient, broad genotyping should return before PD-1/PD-L1 monotherapy is started.

Open questions

  • Now that both intensification strategies improve OS in aggregate (PMIDs: 41104938, 40923797), which baseline features identify patients who gain enough to justify the added toxicity, and which patients do as well on osimertinib alone (PMIDs: 42574006, 42767607)?
  • Can ctDNA clearance select adjuvant duration or safely identify patients who need no three-year therapy?
  • What fraction of adjuvant osimertinib benefit is cure versus delayed recurrence under modern retreatment (Tsuboi 2023, PMID 37272535)?
  • Which post-osimertinib resistance combinations improve OS in mechanism-defined cohorts?
  • How can CNS control be improved for exon 20 insertion disease (Zhou 2023, PMID 37870976)?

References

  1. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009. PMID 19692680
  2. Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018. PMID 29151359
  3. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020. PMID 31751012
  4. Planchard D, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023. PMID 37937763
  5. Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024. PMID 38924756
  6. Wu YL, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32955177
  7. Tsuboi M, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023. PMID 37272535
  8. Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017. PMID 27959700
  9. Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023. PMID 37870976
  10. Shi Y, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014. PMID 24419411
  11. Roper N, et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020. PMID 32483558
  12. Hobor S, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024. PMID 38871738
  13. Leighl NB, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019. PMID 30988079
  14. Rolfo C, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID 34246791
  15. Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
  16. Tian W, et al. Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2022. PMID 35695676
  17. Cho BC, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022. PMID 34911336
  18. Felip E, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024. PMID 38942080
  19. Brown H, et al. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020. PMID 31605792
  20. Papadimitrakopoulou VA, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020. PMID 32861806
  21. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014. PMID 24893891
  22. Thress KS, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015. PMID 25939061
  23. Cancer Genome Atlas Research Network, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014. PMID 25079552
  24. Frankell AM, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023. PMID 37046096
  25. Howlader N, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020. PMID 32786189
  26. Jänne PA, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026;394(1):27-38. PMID 41104938
  27. Yang JC, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693. PMID 40923797
  28. Planchard D, et al. Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2. Lung Cancer. 2026. PMID 42728193
  29. Zhou T, et al. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA. 2026;336(10):838-847. PMID 42574006
  30. Ishida M, et al. Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy. J Thorac Oncol. 2026. PMID 42767607
  31. Hayashi H, et al. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. J Thorac Oncol. 2026;21(9):103894. PMID 42061572
  32. Wu YL, et al. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial. J Thorac Oncol. 2026. PMID 42732874
  33. Liu YT, et al. Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. Signal Transduct Target Ther. 2026;11(1). PMID 42660909
  34. Le X, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026;27(9):1094-1109. PMID 42636833
  35. Soo RA, et al. Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2026. PMID 42833236
  36. Lee CK, et al. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026;21(5):103549. PMID 41534788
  37. [No authors listed]. Correction to Lancet Oncol 2026; 27: 1094-109. Lancet Oncol. 2026;27(10):e450. PMID 42805208
  38. HARMONi-A Study Investigators, Fang W, et al. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026;336:306-314. PMID 42307937
  39. Hong S, et al. Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China. Lancet. 2026. PMID 42933461
  40. Xu CR, et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China. Lancet. 2026. PMID 42933457
  41. Li Z, et al. Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial. J Clin Oncol. 2026. PMID 42928710
  42. Xu Y, et al. Local ablative therapy plus systemic treatment versus systemic therapy alone in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis of randomized trials. Int J Clin Oncol. 2026. PMID 42955614